GENFLEET-B (02595) saw its shares rise more than 6% in morning trading. As of the latest update, the stock was up 5.08%, trading at HK$35.96 with a turnover of HK$16.82 million. The movement follows news that the clinical trial application for its GFS202A injection has been formally accepted by the Center for Drug Evaluation (CDE) as of May 12, with the acceptance number CXSL2600491. Public information indicates that GFS202A is the world's first bispecific antibody targeting both GDF15 and IL-6. A research report from Southwest Securities noted that the company is advancing into major therapeutic areas such as pancreatic cancer, non-small cell lung cancer, and cachexia with its product portfolio, aiming to cover first-line and subsequent treatments, with its product development progress leading globally. The report forecasts revenues of RMB 85 million, RMB 102 million, and RMB 311 million for the years 2026 to 2028, representing year-on-year changes of -35%, +20%, and +205%, respectively. This marks the firm's inaugural coverage of the stock, recommending investors maintain active attention.